

WHAT IS CLAIMED IS:

1. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 Heavy Chain (HC)	SEQ ID NO: 309	SYGVH
CDR2 HC	SEQ ID NO: 310	VIWAGGTTNYNSALMS
CDR3 HC	SEQ ID NO: 311	DGHFHFDF
CDR1 Light Chain (LC)	SEQ ID NO: 303	RASDIIYSNLA
CDR2 LC	SEQ ID NO: 304	AATNLAA
CDR3 LC	SEQ ID NO: 305	QHFVGSSIS

said affinity binding entity capable of binding HLA-A2/Tyr_{D369-377} in an MHC restricted manner.

2. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 Heavy Chain (HC)	SEQ ID NO: 293	TSGMGVS
CDR2 HC	SEQ ID NO: 294	HIYWDDDKRYNPSLKS
CDR3 HC	SEQ ID NO: 295	KDYGSSFYAMHY
CDR1 Light Chain (LC)	SEQ ID NO: 287	KASQDIHNYIA
CDR2 LC	SEQ ID NO: 288	YTSTLQP
CDR3 LC	SEQ ID NO: 289	LQYDNLWT

said affinity binding entity capable of binding HLA-A2/Tyr_{D369-377} in an MHC restricted manner.

3. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 HC	SEQ ID NO: 325	SYDMS
CDR2 HC	SEQ ID NO: 326	YMSSGGGTYYPDVKG
CDR3 HC	SEQ ID NO: 327	HDEITNFDY
CDR1 LC	SEQ ID NO: 319	RASQSI NSLH
CDR2 LC	SEQ ID NO: 320	YASQSI
CDR3 LC	SEQ ID NO: 321	QQSYSWPLT

said affinity binding entity capable of binding HLA-A2/ WT₁₂₆₋₁₃₄ in an MHC restricted manner.

4. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 HC	SEQ ID NO: 341	GYWIE
CDR2 HC	SEQ ID NO: 342	EILPGSGGTNYNEKFKG
CDR3 HC	SEQ ID NO: 343	DSNSFTY
CDR1 LC	SEQ ID NO: 335	SVSSSVDYIH
CDR2 LC	SEQ ID NO: 336	STSILAS
CDR3 LC	SEQ ID NO: 337	QQRSSYT

said affinity binding entity capable of binding HLA-A2/ MAGE-A4₃₂₈₋₃₄₃ in an MHC restricted manner.

5. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 HC	SEQ ID NO: 357	FSSSWMN
CDR2 HC	SEQ ID NO: 358	RIYPGDGDTNYNEKFKG
CDR3 HC	SEQ ID NO: 359	EATTVVAPYYFDY
CDR1 LC	SEQ ID NO: 351	RASENIYRNLA
CDR2 LC	SEQ ID NO: 352	AATNLAD
CDR3 LC	SEQ ID NO: 353	QHFWGTPLT

said affinity binding entity capable of binding HLA-A2/ MAGE-A9₃₄₄₋₃₅₉ in an MHC restricted manner.

6. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 HC	SEQ ID NO: 373	DYNMD
CDR2 HC	SEQ ID NO: 374	DINPNYDTTTYNQKFKG
CDR3 HC	SEQ ID NO: 375	RNYGNYVGFDY
CDR1 LC	SEQ ID NO: 367	KASQRVNNDVA
CDR2 LC	SEQ ID NO: 368	YASNRYT
CDR3 LC	SEQ ID NO: 369	QQDYSSPFT

said affinity binding entity capable of binding HLA-A2/ PAP₃₆₀₋₃₇₅ in an MHC restricted manner.

7. The affinity binding entity of any one of claims 1-6, being selected from the group consisting of an antibody, a CAR and a TCR.

8. The affinity binding entity of claim 7 comprising a therapeutic moiety.
9. The affinity binding entity of any one of claims 7-8, wherein said antibody is a single chain antibody, a bi-specific antibody or a full length antibody.
10. An expression vector comprising a polynucleotide comprising a nucleic acid sequence encoding the affinity binding entity of any one of claims 1-9 operably linked to a cis-acting regulatory element.
11. A cell comprising the expression vector of claim 10.
12. An *in vitro* method of detecting a cancer cell, comprising contacting the cell with the antibody of any one of claims 7-9, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer cell.
13. A method of diagnosing cancer in a subject in need thereof, comprising contacting a cell of the subject with the antibody of any one of claims 7-9, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer.
14. Use of the affinity binding entity of any one of claims 1-9, the vector of claim 10 or the cell of claim 11 in the manufacture of a medicament for treating cancer.

15. The use of claim 14, wherein when said affinity binding entity is for TyrD said cancer is selected from the group consisting of melanoma and glioblastoma;

when said affinity binding entity is for WT1 said cancer is selected from the group consisting of chronic myelocytic leukemia, multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), myelodysplastic syndrome (MDS), mesothelioma, ovarian cancer, gastrointestinal cancers e.g., colorectal cancer adenocarcinoma, thyroid cancer, breast cancer, lung cancer (e.g., non small cell lung cancer), melanoma, osteosarcoma, endometrial cancer, prostate cancer and glioblastoma, T cell leukemia/lymphoma (e.g., ATLL), testicular cancer, head and neck cancer, bladder cancer and esophagus cancer; when said affinity binding entity is for MAGE-A9 said cancer is selected from the group consisting of renal cell carcinoma, bladder cancer, breast cancer and hepatocellular carcinoma; or when said affinity binding entity is for PAP said cancer is selected from the group consisting of prostate cancer.